- Primary research
- Open Access
Hypericin-mediated photodynamic therapy induces apoptosis of myoloma SP2/0 cells depended on caspase activity in vitro
© Zhang et al.; licensee BioMed Central Ltd. 2014
- Received: 27 June 2014
- Accepted: 21 November 2014
- Published: 19 December 2014
Photodynamic therapy (PDT) is becoming a promising therapeutic modality for hematological malignancies. Hypericin is a natural photosensitizer possessing anti-depressant, anti-virus and anti-cancer activities. The present study was designed to explore the effect and mechanism of hypericin-mediated PDT on the mouse multiple myeloma (MM) cells in vitro.
The mouse myeloma SP2/0 cells were incubed with different concentrations of hypericin and then illuminated with different light doses. The inhibitory effect of hypericin-mediated PDT on tumor cell proliferation was assayed by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) method. The apoptosis related morphological changes of SP2/0 cells were observed by microscopy. The biochemical hallmarks of apoptosis such as DNA fragments, mitochondrial membrane potential changes were assessed. The expression of apoptosis related proteins were investigated by western blotting.
Hypericin-mediated PDT induced the proliferation inhibition and apoptosis of tumor cells in a dose dependent manner. Tumor cells showed obvious morphological changes of apoptosis and necrosis and DNA fragmentation after treated by hypericin mediated PDT (0.025 ~ 0.05 μM). The mitochondria membrane potential in SP2/0 cells was decreased significantly after incubated with the 0.025 μM and 0.5 μM hypericin (P < 0.05). The expression level of caspase-3 was decreased, while caspase activity was elevated with the increasing drug dosage. The apoptosis of SP2/0 cells was blocked by a pan-caspase inhibitor Z-VAD-FMK and caspase-3 inhibitor Ac-DEVD-CHO.
Hypericin-mediated PDT induced apoptosis mainly dependent on caspase related pathways. Hypericin-mediated PDT may be a potential and alternative therapy for MM.
- Multiple myeloma
- Hypericin-mediated photodynamic therapy
- SP2/0 cells
Multiple myeloma (MM) as one of the lymphoid neoplasms, is characterized by the accumulation of abnormal plasma cells in bone marrow ,.MM is the second most common hematological malignancy, accounting for 10% of all hematological malignancies. MM can affect various organs function in patients and result in a series of symptoms such as bone pain, renal failure, infection and neurological disorders -. It is estimated that total 14541 cases will suffer MM in the year of 2010 and the number of incidence cases are likely to increase to 21754 by 2020 in India . In addition, the overall survival time for patients with MM ranges from 6 months to 10 years with mean of 3 to 4 years . MM remains an incurable hematological malignancy, despite of conventional and advanced chemotherapy.
Presently, novel therapies are urgently needed. Photodynamic therapy (PDT) is a potential novel anticancer therapy that applied a photosensitizer and light to produce reactive oxygen in cells . PDT can inactivate tumor cells in autologous bone marrow grafts and shows benefits in bone marrow transplantation substantially . PDT has been applied in eradicating the malignant cells of the autograft in the autologous bone marrow transplantation for MM treatment . Additionally, it is reported that PDT exerts stronger cytotoxicity in chronic myeloid leukemia (CML) cells than normal granulocyte/macrophage progenitors and PDT can eliminate CML cells from malignant-normal bone marrow mononuclear cells mixture . PDT is becoming a promising therapeutic modality for hematological malignancies, such as leukemia , lymphoma  and MM .
Hypericin, a natural polycyclic quinone, is mainly extracted from the plants of hypericum genus . Hypericin has been regarded as a promising photosensitizing agent for its characteristic of light-dependent antineoplastic and antiviral activity . Hypericin-mediated PDT has obtained increasing interests as a potential treatment for various cancers -. Currently, multiple pathways have been found to involved in the tumor cell death program induced by hypericin-mediated PDT, such as mitochondrial pathway ,, lysosomal damage , alternation of intracellular pH level , _ENREF_19, Bcl-2 phosphorylation by CDK-1  as well as the increase of intracellular Ca2+ stimulated apoptosis -. However, the mechanism underlying hypericin-mediated PDT for MM suppression has been not clarified clearly.
In this study, we explore the mechanism of MM treatment and the type of cell death induced by PDT with hypericin by SP2/0 cells. The cellular morphology and the cell proliferation of SP2/0 cells were investigated at different concentrations of hypericin. The changes in the mitochondrial membrane potential and the activation of Caspase related pathways were further assessed. The aim of the present study was to investigate the effect and mechanism of hypericin-mediated PDT on the mouse MM cells in vitro.
Hypericin preparation and cell culture
Hypericin powder (Beijing Standard Herbs Medical Science & Technology Development Co. LTD., Beijing, China) with purity > 98% was determined by high-performance liquid chromatography (HPLC). A stock solution of hypericin (10 mM) was prepared with dimethyl sulfoxide (DMSO; Sigma) and stored at −20°C in the dark. Immediately before each experiment, the working solution of hypericin was diluted in RPMI1640 medium without serum to obtain a final concentration.
The mouse myeloma cell line SP2/0 (ATCC) was from American Type Culture Collection. The cells were cultured in RPMI1640 medium supplemented with 10% calf serum, 2.2 g/l NaHCO3, 100 U/ml penicillin, and 100 g/ml streptomycin. Cells were maintained in a humidified atmosphere with 5% CO2 at 37°C until the logarithmic growth phase based on the cell growth curve. The adherent cells were displaced by rinsing with 0.25% trypsin. Then, the adherent and suspension cells were harvested for the following experiments.
SP2/0 cells (5 × 104 cells/ml) were seeded on 96-well plates (100 μl/well) and incubated with hypericin at different concentration (0.001, 0.01, 0.1, 1 and 10 μM) for 16 hours in the dark. Cells were given external 7 cm illumination treatment on a plastic diffuser sheet above a set of 6 yellow L18W/30 lamps (CH Lighting, Zhejiang, China) with the maximum spectrum range of 570–620 nm. Irradiation intensity was detected to be under 13000 lux by TES-1332A (TES, Taiwan, China). The total light doses were determined to be 2.82, 5.64, 8.46, 11.28 and 14.10 J/cm2 by a photometer. During the illumination, the temperature of the samples ranged from 32 to 37°C. After PDT treatment, cells were maintained for 24 hours at 37°C in a humidified atmosphere of 95%, 5% CO2 until further analysis.
The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay
In order to determine the optimal hypericin concentration or irradiation dose for PDT treatment, we performed MTT assay to analyze the proliferation of SP2/0 cells . Briefly, SP2/0 cells at a final density of 5 × 104 cells/ml (100 μl/well), were incubated with hypericin at a concentration gradient from 0.001 to 10 μM for 16 hours in the dark. The cell plates were illuminated with different light dose of 0, 2.82, 5.64, 8.46, 11.28 and 14.10 J/cm2, and then incubated for 24 hours in the dark. To obtain the IC50, SP2/0 cells were treated with indicated concentrations of hypericin (0, 0.0125, 0.025, 0.05 and 0.1 μM) for 16 hours in the dark. Subsequently, the cells were illuminated at a light dose of 11.28 J/cm2 for 24 hours in the dark.
SP2/0 cells without any treatment were set as controls. The MTT assay was performed for SP2/0 cells at each condition according to the manufacturer’s instructions. In brief, 10 μl of MTT (5 mg/ml; Sigma) was added in each well for 4 hours at 37°C. After removal of the medium, the MTT crystals were dissolved with 100 μl DMSO for 15 min. The absorbance at 550 nm was measured by a Multiskan Spectrum 1500 (Thermo Electron Corporation, USA). The inhibition rate of cell proliferation was calculated as follows: (A550control -A550treated) / A550control × 100% and the IC50 value was obtained by Logit method .
Light and fluorescence microscopy
SP2/0 cells (1 × 105cells/ml) were seeded into the 6-well plates (2 mL/well) and incubated with hypericin at the final concentrations of 0.025, 0.05 or 0.1 μM for 16 hours in the dark. Subsequently, the plates were illuminated at a light dose of 11.28 J/cm2 for 24 h. The adherent and suspension cells were collected for the following morphological analysis according to the method described above.
A part of cells were harvested and observed by a phase-contrast microscopy. Some cells were collected for Hoechst 33342/propidium iodide (PI) co-staining . SP2/0 cells were stained with Hoechst 33342 (5 μg/ml) and PI (5 μg/ml) at room temperature for 10 min, then examined under a fluorescence microscopy (E600, Nikon, Japan) with excitation at 360 nm . Intact blue nuclei of viable cells, condensed/fragmented bright blue nuclei of apoptotic (early or late) cells and pink nuclei of necrotic cells can be observed. The number of apoptotic or necrotic cells was counted in a total of 200 cells from 5 random fields.
Transmission electron microscopy (TEM)
SP2/0 cells (1 × 105cells/ml, 2 mL/well) treated with hypericin (0.025, 0.05 or 0.1 μM) and illumination (11.28 J/cm2) were collected for TEM examination. Samples were prepared as described previously . The cells were fixed with 2.5% glutaraldehyde, followed by 1% OsO4 and then dehydrated with acetone. They were embedded in Epon812-resin mixture. Serial sections (about 50 nm) were obtained by ultra-microtome. Sections were stained with sodium acetate and lead citrate and then viewed by a Hitachi H-7000/STEM electron microscope (Hitachi Inc., Tokyo, Japan) at 75 kV.
SP2/0 cells with hypericin (0.025, 0.05 and 0.1 μM) and illumination (11.28 J/cm2) were used for this experiment. The suspension cells and adhesive cells on the 6-well plates were all collected for DNA extraction following the manufacturer’s instructions of DNA Ladder Extraction Kit with Spin Column (Beyotime Institute of Biotechnology, China). The DNA extractions (40 μg) were separated on 1.0% agarose gel containing ethidium bromide (EB) and were visualized under UV light. Standard molecular weight markers (Fermentas, MBI) were run on the left-hand lane of the gel.
The 5, 5’, 6, 6’-tetrachloro-1, 1’, 3, 3’-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1) staining
In order to explore the changes in the membrane potential, we carried out JC-1 staining for SP2/0 cells intervened by hypericin (0, 0.025 and 0.05 μM) and illumination (11.28 J/cm2). The collapse of the mitochondrial membrane was measured using a mitochondrial membrane potential assay kit with JC-1 (Beyotime Institute of Biotechnology, China) . JC-1 formed aggregates in the mitochondria at relatively high membrane potential exhibiting red-orange fluorescent at 590 nm. The JC-1 monomers distributed in the cytoplasm of cells with low potential and emitted a green fluorescent at 529 nm. After JC-1 staining, cells were analyzed by flow cytometry with green emission in channel 1 (FL1) and red emission in channel 2 (FL2). The relative ratio of JC-1 aggregate (FL2, red fluorescence intensity) to monomer (FL1, green fluorescence intensity) was calculated. A decrease in this ratio was defined as the depolarization of the mitochondrial membrane potential.
Propidium iodide (PI) staining
To evaluate the effects of caspase inhibitors (pan-caspase inhibitor Z-VAD-FMK or caspase-3 inhibitor Ac-DEVD-CHO) on apoptosis mediated by hypericin with PDT, the PI staining was carried out. The caspase inhibitors were dissolved in DMSO at a storage 20 mM concentration. SP2/0 cells were pre-incubated with the pan-caspase inhibitor (100 μM) or caspase-3 inhibitor (100 μM) for 1 h, and then exposed to 0.05 μM hypericin for 16 h in the dark. Preliminary experiment indicated that 0.125% DMSO had little effect on the cell death and proliferation. For PI staining, the caspase inhibitors were dissolved in 0.05% DMSO that was safe for SP2/0 cells. After illuminated at 11.28 J/cm2 for 24 h, SP2/0 cells were harvested, fixed in 70% ethanol and stored at 4°C overnight. Then, cells were stained with PBS containing 40 μg/mL RNase and 10 μg/mL PI at room temperature for 30 min in the dark. Cells were analyzed using an FACS-Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA). The cells during apoptosis were obtained from the distinct sub-G1 region of the DNA distribution histograms. At least 20,000 events were counted for each sample.
Caspase-3 activity assay
Western blot analysis was performed as previously described -. Protein samples (40 μg) were separated by 8-12% (8% for PARP-1; 10% for AIF, β-actin; 12% for Bcl-2, Bax, Cytochrome c, Histone 2A, Caspase-3) sodium dodecyl sulfate-polyacrylamide gels electrophoresis and transferred to polyvinylidene fluoride membrane (Immobilon PVDF, Millipore). The membranes were blocked in 10% non-fat dried milk in TBS-T (10 mM Tris–HCl (pH 8.0), 150 mM NaCl, and 0.1% Tween) for 2 hours at room temperature. Then the membranes were incubated with the primary antibodies of anti-Bcl-2 rabbit monoclonal antibody (1:1000), anti-Bax rabbit monoclonal antibody (1:1000), anti-caspase-3 rabbit polyclonal antibody (1:1000), anti-PARP rabbit polyclonal antibody (1:1000), anti-β-actin mouse polyclonal antibody (1:1000), anti-cytochrome c rabbit monoclonal antibody (1:1000), anti-AIF rabbit monoclonal antibody (1:1000), and anti-H2AX rabbit monoclonal antibody (1:500), respectively, overnight at 4°C. All the antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Subsequently, membranes were washed three times with Tris-bufffered saline, 0.1% Tween-20 and then incubated with the peroxidase-conjugated secondary antibodies for 1 h. The membranes were washed three times again and developed using enhanced chemiluminescence (ECL, Amersham Biosciences). Bands were visualized using the ChemiDoc™ XRS+ System with Image Lab™ Software (Bio-rad, USA). Protein expressions were quantified by densitometry analyzed using Quantity One 4.5.2 software (Bio-Rad, Hercules, USA).
All the data were displayed as mean ± standard deviation (SD). All the statistical analysis was performed by SPSS17.0 statistical software. Differences among groups were analyzed with S-N-K followed by One-Way ANOVA. P value < 0.01 was considered to be statistically significant.
Hypericin mediated PDT inhibited the proliferation of SP2/0 cells
There was a positive linear correlation between the inhibition rate and hypericin concentration (R2 = 0.955) and the value of IC50 was 0.035 ± 0.003 μM at condition of hypericin (0, 0.0125, 0.05 or 0.1 μM) with light dose of 11.28 J/cm2 (Figure 1B). These results suggested that hypericin-mediated PDT inhibited the proliferation of SP2/0 cells effectively in a concentration and light-dose dependent manner.
Hypericin-mediated PDT induced obvious morphological changes of apoptosis in SP2/0 cells
Furthermore, TEM analysis revealed that hypericin-mediated PDT induced obvious morphological changes of SP2/0 cells. The control cells showed abundant cytoplasm and apparent nuclei with uniformly dispersed chromatin. After exposed to 0.025 μM hypericin with PDT, cells exhibited the typical characteristics of early stage apoptosis such as nuclear membrane contraction and chromatin marginalization. When exposed to 0.05 μM hypericin with PDT, cells were characterized by nuclear fragmentation, intense vacuolization and a large number of apoptotic body formations. At the condition of 0.1 μM hypericin with PDT, there appeared the necrotic cell death, which displayed ruptured plasma membrane, swollen mitochondrial, irregular chromatin destruction (Figure 2C).
Hypericin-mediated PDT induced DNA fragmentation in SP2/0 cells
Hypericin-mediated PDT induced loss of mitochondria membrane potential in SP2/0 cells
Hypericin-mediated PDT induced apoptosis dependent on caspase
MM is the most common bone marrow malignancy. It is reported that there are 114,000 cases diagnosed with MM and 80,000 deaths resulting from MM in 2010 worldwide . MM remains an incurable bone malignancy with severe complications and poor prognosis for MM patients. The increasing studies for MM treatment contribute to the evolution of therapies, the increase of survival time and the improvement of life quality for patients. Hypericin-mediated PDT is reported to be an attractive candidate treatment modality for human cancer cells. The evidence of the inhibitive effect of hypericin-mediated PDT on MM is insufficient. In this study, we further explored the mechanism of the apoptosis of mouse myeloma SP2/0 cells induced by hypericin-mediated PDT at different concentrations of hypericin.
Our results showed that the combination of hypericin with PDT showed great inhibitive effects on the proliferation of SP2/0 cells and led to extensive apoptosis. After tumor cells were incubated with different concentrations of hypericin (0.01-10 μM) and then exposed to illumination with different light doses (0–14.10 J/cm2), data from MTT assay revealed that hypericin or illumination treatment alone had no obvious effect on inhibiting the proliferation of SP2/0 cells. Hypericin combined with illumination caused significant drug concentration- and light intensity-dependent manner in the inhibition of SP2/0 cells proliferation. The metabolic activity of SP2/0 cells was reduced significantly with the increasing hypericin concentration and light dose. Additionally, we found that under the same concentration of hypericin, high light dose (11.28 and 14.10 J/cm2) caused comparable effect on the cell proliferation inhibition, and the higher concentrations of hypericin (1 and 10 μM) caused equal inhibitory effect on the tumor cell proliferation, under the same illumination, which indicated that there might be a saturation of photochemical dose in PDT treatment on the MM. In order to avoid the damage caused by excess photosensitizing drug, the optimal treatment condition leading to the appropriate energy state results for MM patients should be further studied.
Apoptosis has been determined to be the most prominent event in the tumor tissue destruction induced by hypericin-mediated PDT. In order to assess the involvement of apoptosis in tumor response to hypericin-mediated PDT, the hallmarks of apoptosis including DNA fragmentation and morphological changes were investigated in this paper. Results showed that low doses of PDT with hypericin (0.025 and 0.05 μM) induced apparent morphological and biochemical characteristics of apoptosis in SP2/0 cells such as cell shrinkage, chromatin condensation, formation of apoptotic bodies as well as DNA laddering, while high dose of PDT with hypericin (0.1 μM) led to cell necrosis (Figures 2 and 3). As outlined in previous studies, apoptosis induced by PDT can be observed at lower hypericin concentrations and fewer light intensities, whereas necrosis occurs at high hypericin concentrations and light intensities ,, which is consistent with our findings. The transitions from apoptosis to necrosis in a drug and light dose-dependent manner induced by hypericin with PDT have also been observed in HeLa cells and human epidermoid carcinoma cells in vitro,. All these showed that hypericin-mediated PDT is a potent inducer of apoptosis or necrosis in MM SP2/0 cells depended on the dosage of PDT, despite of the factors such as the location of the photosensitizer, the nature of photosensitizer as well as the genetic and metabolic potential of the cell type.
It is demonstrated that the apoptosis induced by hypericin-mediated PDT mainly resulted from the activation of apoptosis related pathways in response to the oxidative stresss and other signals . It is reported that the apoptosis pathways induced by hypericin-mediated PDT are involved with plasma membrane death receptors, mitochondria, lysosomes and ER, caspases, and Bcl-2 family proteins . Bcl-2 family proteins play key roles in the mitochondria-mediated cell death . The expression of Bcl-2 family proteins can induce the mitochondrial membrane permeabilization, which causes the release of caspases or apoptosis inducing factor (AIF) . The up-regulation of Bax/Bcl-2 ratio is found to be associated with the decrease of mitochondrial membrane potential that inhibits the growth of cancer cell growth .
In the present study, results of western blotting suggested that the expression of anti-apoptotic Bcl-2 protein was decreased and pro-apoptotic Bax protein was increased induced by hypericin-mediated PDT and thus shifted the Bax/Bcl-2 ratio that leaded to loss of the mitochondrial membrane potential in favor of cytochrome c and AIF release. In the apoptosis process, the release of cytochrome c induced the activation of caspase-9 and then activates caspase-3 . Caspase-3-mediated cleavage of the 116-kDa PARP protein into 89-kDa fragments is a hallmark of apoptosis . The present study also showed that caspase-3 activity was increased that contributed to PARP cleavage and DNA degradation.
In fact, cytochrome c-mediated capsase dependent apoptotic pathway and AIF mediated caspase independent apoptotic pathway are complicated but not completely independent. AIF in the cytosol could promote cytochrome c to be released from mitochondria and the activated caspases also facilitate translocation of AIF from mitochondria to the nucleus  _ENREF_34. Besides, the present study further showed that the apoptosis induced by hypericin-mediated PDT was inhibited significantly by the pan-caspase inhibitor zVAD-fmk or special caspase-3 inhibitor Ac-DEVD-CHO. All these indicated that AIF release might be facilitated by casapse and hyerpicin with PDT induced apoptosis mainly depended on caspase-mediated cell death pathways.
Hypericin-mediated PDT could significantly inhibit the proliferation and induce apoptosis in myeloma SP2/0 cells. The apoptosis induced by hypericin-mediated PDT mainly depended on the caspase-mediated cell death pathway. Hypericin-mediated PDT may be a promising and alternative strategy for the treatment of MM.
We wish to express our warm thanks to Fenghe (Shanghai) Information Technology Co., Ltd. Their ideas and help gave a valuable added dimension to our research.
- BladÉ J, Samson D, Reece D, Apperley J, BJÖrkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high‐dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998, 102 (5): 1115-1123.View ArticlePubMedGoogle Scholar
- Greene FL: AJCC Cancer Staging Manual, Volume 1. 2002, Springer, New YorkView ArticleGoogle Scholar
- Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC: Multiple myeloma. Lancet. 2009, 374 (9686): 324-339.View ArticlePubMedGoogle Scholar
- Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma. Arch Intern Med. 1990, 150 (8): 1693-1695.View ArticlePubMedGoogle Scholar
- Twomey JJ: Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med. 1973, 132 (4): 562-565.View ArticlePubMedGoogle Scholar
- Dispenzieri A, Kyle RA: Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol. 2005, 18 (4): 673-688.View ArticlePubMedGoogle Scholar
- Takiar R, Nadayil D, Nandakumar A: Projections of number of cancer cases in India (2010–2020) by cancer groups. Asian Pac J Cancer Prev. 2010, 11 (4): 1045-1049.PubMedGoogle Scholar
- Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA: International staging system for multiple myeloma. J Clin Oncol. 2005, 23 (15): 3412-3420.View ArticlePubMedGoogle Scholar
- Oleinick NL, Morris RL, Belichenko I: The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci. 2002, 1 (1): 1-21.View ArticlePubMedGoogle Scholar
- Sieber F: Phototherapy, photochemotherapy, and bone marrow transplantation. J Hematother. 1993, 2 (1): 43-62.View ArticlePubMedGoogle Scholar
- Brasseur N, Menard I, Forget A, Jastimi R, Hamel R, Molfino N, Lier J: Eradication of Multiple Myeloma and Breast Cancer Cells by TH9402‐mediated Photodynamic Therapy: Implication for Clinical Ex Vivo Purging of Autologous Stem Cell Transplants. Photochem Photobiol. 2000, 72 (6): 780-787.View ArticlePubMedGoogle Scholar
- Huang H, Chen Y, Chen W, Wu Y: Purging efficacy of ZnPcH(1)-based photodynamic therapy on chronic myeloid leukemia bone marrow. Int J Lab Hematol. 2011, 33 (5): 477-482.PubMedGoogle Scholar
- Barth BMI, Altinoğlu E, Shanmugavelandy SS, Kaiser JM, Crespo-Gonzalez D, DiVittore NA, McGovern C, Goff TM, Keasey NR, Adair JH: Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano. 2011, 5 (7): 5325-5337.View ArticlePubMedGoogle Scholar
- Shahzidi S, Čunderlíková B, Więdłocha A, Zhen Y, Vasovič V, Nesland JM, Peng Q: Simultaneously targeting mitochondria and endoplasmic reticulum by photodynamic therapy induces apoptosis in human lymphoma cells. Photochem Photobiol Sci. 2011, 10 (11): 1773-1782.View ArticlePubMedGoogle Scholar
- Agostinis P, Vantieghem A, Merlevede W, de Witte PA: Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol. 2002, 34 (3): 221-241.View ArticlePubMedGoogle Scholar
- Lavie G, Mazur Y, Lavie D, Meruelo D: The chemical and biological properties of hypericin—a compound with a broad spectrum of biological activities. Med Res Rev. 1995, 15 (2): 111-119.View ArticlePubMedGoogle Scholar
- Cole CD, Liu JK, Sheng X, Chin SS, Schmidt MH, Weiss MH, Couldwell WT: Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in a GH4C1 rat tumor model. J Neurooncol. 2008, 87 (3): 255-261.View ArticlePubMedGoogle Scholar
- Zupko I, Kamuhabwa AR, D'Hallewin MA, Baert L, De Witte PA: In vivo photodynamic activity of hypericin in transitional cell carcinoma bladder tumors. Int J Oncol. 2001, 18 (5): 1099-1105.PubMedGoogle Scholar
- Liu CD, Kwan D, Saxton RE, McFadden DW: Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo. J Surg Res. 2000, 93 (1): 137-143.View ArticlePubMedGoogle Scholar
- Vantieghem A, Assefa Z, Vandenabeele P, Declercq W, Courtois S, Vandenheede JR, Merlevede W, de Witte P, Agostinis P: Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis. Involvement of cytochrome c and procaspase-3 activation in the mechanism of apoptosis. FEBS Lett. 1998, 440 (1–2): 19-24.View ArticlePubMedGoogle Scholar
- Berlanda J, Kiesslich T, Oberdanner CB, Obermair FJ, Krammer B, Plaetzer K: Characterization of apoptosis induced by photodynamic treatment with hypericin in A431 human epidermoid carcinoma cells. J Environ Pathol Toxicol Oncol. 2006, 25 (1–2): 173-188.View ArticlePubMedGoogle Scholar
- Ali SM, Olivo M: Bio-distribution and subcellular localization of Hypericin and its role in PDT induced apoptosis in cancer cells. Int J Oncol. 2002, 21 (3): 531-540.PubMedGoogle Scholar
- Miccoli L, Oudard S, Sureau F, Poirson F, Dutrillaux B, Poupon MF: Intracellular pH governs the subcellular distribution of hexokinase in a glioma cell line. Biochem J. 1996, 313 (Pt 3): 957-962.View ArticlePubMed CentralPubMedGoogle Scholar
- Miccoli L, Beurdeley-Thomas A, De Pinieux G, Sureau F, Oudard S, Dutrillaux B, Poupon MF: Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria. Cancer Res. 1998, 58 (24): 5777-5786.PubMedGoogle Scholar
- Vantieghem A, Xu Y, Assefa Z, Piette J, Vandenheede JR, Merlevede W, De Witte PA, Agostinis P: Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. J Biol Chem. 2002, 277 (40): 37718-37731.View ArticlePubMedGoogle Scholar
- Assefa Z, Vantieghem A, Declercq W, Vandenabeele P, Vandenheede JR, Merlevede W, de Witte P, Agostinis P: The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin. J Biol Chem. 1999, 274 (13): 8788-8796.View ArticlePubMedGoogle Scholar
- Hendrickx N, Volanti C, Moens U, Seternes OM, de Witte P, Vandenheede JR, Piette J, Agostinis P: Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells. J Biol Chem. 2003, 278 (52): 52231-52239.View ArticlePubMedGoogle Scholar
- Hendrickx N, Dewaele M, Buytaert E, Marsboom G, Janssens S, Van Boven M, Vandenheede JR, de Witte P, Agostinis P: Targeted inhibition of p38alpha MAPK suppresses tumor-associated endothelial cell migration in response to hypericin-based photodynamic therapy. Biochem Biophys Res Commun. 2005, 337 (3): 928-935.View ArticlePubMedGoogle Scholar
- Wessels JT, Busse AC, Rave-Frank M, Zanker S, Hermann R, Grabbe E, Muller GA: Photosensitizing and radiosensitizing effects of hypericin on human renal carcinoma cells in vitro. Photochem Photobiol. 2008, 84 (1): 228-235.PubMedGoogle Scholar
- Räz B, Iten M, Grether-Bühler Y, Kaminsky R, Brun R: The Alamar Blue® assay to determine drug sensitivity of African trypanosomes (< i > Tb rhodesiense</i > and < i > Tb gambiense</i>) in vitro. Acta Trop. 1997, 68 (2): 139-147.View ArticlePubMedGoogle Scholar
- Yuan Y-J, Ge Z-Q, Li J-C, Wu J-C, Hu Z-D: Differentiation of apoptotic and necrotic cells in suspension cultures of Taxus cuspidata by the combined use of fluorescent dying and histochemical staining methods. Biotechnol Lett. 2002, 24 (1): 71-76.View ArticleGoogle Scholar
- Shimizu S, Eguchi Y, Kamiike W, Itoh Y, Hasegawa J, Yamabe K, Otsuki Y, Matsuda H, Tsujimoto Y: Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res. 1996, 56 (9): 2161-2166.PubMedGoogle Scholar
- Cossarizza A, Franceschi C, Monti D, Salvioli S, Bellesia E, Rivabene R, Biondo L, Rainaldi G, Tinari A, Malorni W: Protective effect of N-acetylcysteine in tumor necrosis factor-alpha-induced apoptosis in U937 cells: the role of mitochondria. Exp Cell Res. 1995, 220 (1): 232-240.View ArticlePubMedGoogle Scholar
- Garner DL, Thomas CA: Organelle-specific probe JC-1 identifies membrane potential differences in the mitochondrial function of bovine sperm. Mol Reprod Dev. 1999, 53 (2): 222-229.View ArticlePubMedGoogle Scholar
- Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F, Xu R: Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res. 2005, 65 (5): 1687-1692.View ArticlePubMedGoogle Scholar
- Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu R, Fan ST: FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis. 2004, 25 (12): 2397-2405.View ArticlePubMedGoogle Scholar
- Xu R, Harrison PM, Chen M, Li L, Tsui TY, Fung PC, Cheung PT, Wang G, Li H, Diao Y, Krissansen GW, Xu S, Farzaneh F: Cytoglobin overexpression protects against damage-induced fibrosis. Mol Ther. 2006, 13 (6): 1093-1100.View ArticlePubMedGoogle Scholar
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014 [Epub ahead of print]Google Scholar
- Agostinis P, Assefa Z, Vantieghem A, Vandenheede JR, Merlevede W, De Witte P: Apoptotic and anti-apoptotic signaling pathways induced by photodynamic therapy with hypericin. Adv Enzyme Regul. 2000, 40: 157-182.View ArticlePubMedGoogle Scholar
- Ali SM, Olivo M: Mechanisms of action of phenanthroperylenequinones in photodynamic therapy (review). Int J Oncol. 2003, 22 (6): 1181-1191.PubMedGoogle Scholar
- Moor AC: Signaling pathways in cell death and survival after photodynamic therapy. J Photochem Photobiol B. 2000, 57 (1): 1-13.View ArticlePubMedGoogle Scholar
- Kiesslich T, Krammer B, Plaetzer K: Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. Curr Med Chem. 2006, 13 (18): 2189-2204.View ArticlePubMedGoogle Scholar
- Chao DT, Korsmeyer SJ: BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998, 16 (1): 395-419.View ArticlePubMedGoogle Scholar
- Kroemer G, Galluzzi L, Brenner C: Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007, 87 (1): 99-163.View ArticlePubMedGoogle Scholar
- Cheng C-Y, Su C-C: Tanshinone IIA may inhibit the growth of small cell lung cancer H146 cells by up-regulating the Bax/Bcl-2 ratio and decreasing mitochondrial membrane potential. Mol Med Reports. 2010, 3 (4): 645-650.Google Scholar
- Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG, Huang DC, Cecconi F, Kuida K, Tomaselli KJ: Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature. 2002, 419 (6907): 634-637.View ArticlePubMedGoogle Scholar
- Pieper AA, Verma A, Zhang J, Snyder SH: Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci. 1999, 20 (4): 171-181.View ArticlePubMedGoogle Scholar
- Cregan SP, Dawson VL, Slack RS: Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene. 2004, 23 (16): 2785-2796.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.